Where are the new therapies for anxiety and obsessive-compulsive disorders?

IDrugs

Volumn 4, Issue 9, 2001, Pages 1031-1042

  Moret, Chantai ^a   Briley, Mike ^a  

^a NeuroBiz Consulting and Communication   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0142176196     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (154)

1. Stoudemire A: Epidemiology and psychopharmacology of anxiety in medical patients. J Clin Psychiatry (1996) 57:64-72.
2. Clement Y, Chapouthier G: Biological bases of anxiety. Neurosci Biobehav Re v (1998) 22:623-633.
3. Hoehn-Saric R: Generalised anxiety disorder: Guidelines for diagnosis and treatment. CNS Drugs (1998) 9:85-98.
4. Norman TR, Judd FK, Marriott PF, Burrows GD: Physical treatment of anxiety: the benzodiazepines. In: Handbook of anxiety, Roth M, Noyes R, Burrows GD (Eds), Elsevier Science Publishers, Amsterdam (1988)335-385.
5. Laux G: Current status of treatment with benzodiazepines. Nervenarzt (1995) 66:311 -322.
6. Ballenger JC, Mcdonald S, Noyes R, Rickets K, Sussman N, Woods S, Patin J, Singer J: The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist abecarnil (ZK-112-119) in generalized anxiety disorder. Psychopharmacol Bull (1991) 27:171179.
7. Lydiard RB, Ballenger JC, Rickels K: A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group. J Clin Psychiatry (1997) 58(Suppl 11 ):11 -18.
8. Small GW, Bystritsky A: Double-blind, placebo-controlled trial of two doses of abecarnil for geriatric anxiety. J Clin Psychiatry (1997) 58(Suppl11):24-9.
9. Neurogen Corporation. Anxiety/depression. Company Website (2001) http://www.neurogen.com/pipeline/anxiety.htm
10. Hoehn-Saric R, McLeod DR, Zmmerii WD: Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry (1988) 49:293301.
11. Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L: Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand (1997) 95:444-50.
12. McLeod DR, Hoehn-Saric R, Porges SW, Kowalski PA, Clark CM: Therapeutic effects of imipramine are counteracted by its metabolite, desipramine, in patients with generalized anxiety disorder. J Clin Psychopharmacol (2000) 20:615-21.
13. Rickels K, Schweizer E: The clinical course and long-term management of generalized anxiety disorder. J Clin Psychopharmacol (1990) 10:101S-110S.
14. Kelsey JE: Efficacy, safety, and toterabilfty of venlafaxine XR in generalized anxiety disorder. Depress Anxiety (2000) 12(Suppl 1):81-4.
15. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E: Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder - A 6month randomized controlled trial. J Am Mod Assoc (2000) 283:3082-3088. • This study is the first placebo-controlled demonstration of the long-term efficacy, rapid action, safety and once-daily administration of venlafaxine in GAD.
16. Feighner JP: Overview of antidepressants currently used to treat anxiety disorders. J Clin Psychiatry (1999) 60(Suppl 22):18-22. • This comprehensive review shows that TCAs are effective across the anxiety disorders, while SSRIs are useful in panic disorder and OCD. TCAs cause serious adverse events, and SSRIs are slow to act and their efficacy is limited in GAD. Newer antidepressants, mirtazapine, nefazodone and venlafaxine XR are effective with good safety and tolerabllity.
17. Chopin P, Moret C, Briley M: Neuropharmacology of 5hydroxytryptamine1B/D receptor ligands. Pharmacol Trier (1994) 62:385-405.
18. Stahl SM: Essential Psychopharmacology, Cambridge University Press, Cambridge (1996).
19. Lucki l: Serotonin receptor specificity in anxiety disorders. J Clin Psychiatry (1996) 57(Suppl 6):5-10.
20. Stahl SM: Mixed depression and anxiety: serotoninIA receptors as a common pharmacologie ink. JClin Psychiatry (1997) 56(Suppl 8)20-6.
21. 1A receptor agonists are all characterized by an apparently narrow therapeutic index.
22. Goa KL, Ward A: Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiofytic. Drugs (1986) 32:114-29.
23. Gammans RE, StringfeHow JC,' Hvizdos AJ, Sektehamel RJ, Cohn JB, Wfcox CS, Fabre LF, Pecknold JC, Smfth WT, Pickels K: Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-anarysis of eight randomized, controlled studies. Neuropsychobiology (1992) 25:193-201.
24. Bames NM, Sharp T: A review of central 5-HT receptors and their function. Neuropharmacology (1999) 38:1083-1152.
25. Blier P, de Montigny C: Current advances and trends in the treatment of depression. Trends Pharmacol Sei (1994) 15:220-226.
26. Blier P, de Montigny C: Possible serotonergic mechanisms underlying the antidepressarrt and anti-obsessive-compulsive disorder responses. /o/Psyc/7/auy (1998) 44:313-323.
27. Temple Jr D: Antidepressants: Clinical and neuropharmacologic considerations relevant to future drug discovery and development. Expert Opin Invest Drugs (1995) 4:909-914.
28. Hadrav V, Blier P, Dennis T, Ortemann C, de Montigny C: Characterization of 5-hydroxytryptamine 1A properties of flesinoxan: in vivo electrophysiology and hypothermia study. Neuropharmacology (1995) 34:1311 -1326.
29. Rickeis K, Schweizer E, DeMartinis N, Mandos L, Mercer C: Gepirone and diazepam in generalized anxiety disorder: A placebocontrolled trial. JClin Psychopharmacol (1997) 17:272-277.
30. Bradford LD, Stevens G: Double-blind, placebo controlled fixed dose study of flesinoxan in generalized anxiety disorder. Am Coll Neuropsychopharmacol (1994) 167.
31. Rasmussen K, Rocco VP: Recent progress in serotonin. Annu Rep Med Chem (1995) 30:1 -9.
32. Ballenger JC: New treatments for panic. Eur Psychiatry (1998) 13:753-81 S.
33. Ballenger JC: Current treatments of the anxiety disorders in adults. Biol Psychiatry (1999) 46:1579-1594.
34. Tiller JW, Bouwer C, Behnke K: Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder. Int Clin Psychopharmacol (1997)12(Suppl6):S27-30.
35. Garcia-Borreguero D, Lauer CJ, Ozdaglar A, Wiedemann K, Holsboer F, Krieg JC: Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A. Pharmacopsychiatry (1992)25:261-4.
36. Bakish D, Saxena BM, Bowen R, D'Souza J: Reversible monoamine oxidase-A inhibitors in panic disorder. Clin Neuropharmacol (1993) 16(Suppl2):S77-82.
37. Van VCet IM, Westenberg HGM, Den Boer JA: MAO inhibitors in panic disorder: Clinical effects of treatment with brofaromine: A double Wind placebo controlled study. Psychopharmacology (1993) 112:483-489.
38. Buller R, Jorga KM: Monoamine oxidase inhibitors (including the newer reversible compounds). In: Anxiolytics, Briley M & Nutt D (Eds), Birkhäuser Verlag, Basel (2000) 41-53.
39. Griebel G, Perrault G, Sanger DJ: Behavioural profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs. Psychopharmacology (1997) 131:180-186.
40. Mavissakalian MB, Perel JM: The side effects burden of extended imipramine treatment of panic disorder. J Clin Psychopharmacol (2000) 20:547-555.
41. Papp LA, Schneier FR, Fyer AJ, Leibowitz MR, Gorman JM, Coplan JD, Campeas R, Fallon BA, Klein DF: Clomipramine treatment of panic disorder: pros and cons. J Clin Psychiatry (1997) 58:423-5.
42. Jefferson JW: Antidepressants in panic disorder. J Clin Psychiatry (1997)58(Suppl2):20-24.
43. Mavissakalian MR, Perel JM: Imipramine dose-response relationship in panic disorder with agoraphobia. Preliminary findings. Arch Gen Psychiatry (1989) 46:127-31.
44. Ansseau M, Von Frenckell R, Serre C: Pilot study of milnacipran in panic disorder. Bur Psychiatry (1391) 6:103-105.
45. Baldwin DS, Birtwistle J: Selective serotonin-reuptake inhibitors in anxiety disorders: room for improvement. In: Anxiolytics, Briley M & Nutt D (Eds), Birkhäuser Verlag, Basel (2000) 55-75. • A recent and complete review of SSRIs in anxiety disorders such as GAD, panic disorder, social phobia, PTSD and OCD.
46. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, Calberg H, Judge R, Ohrstrom JK, Manniche PM: Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry (1995) 167:374-379.
47. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP: Doubleblind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry (1998) 155:36-42.
48. den Boer JA: Pharmacotherapy of panic disorder: differential efficacy from a clinical viewpoint. J Clin Psychiatry (1998) 59(Suppl 8):30-36.
49. Peckndd JC, Luthe L, Scott-Fleury M-H, Jenkins S: Gepirone and the treatment of panic disorder: An open study. J Clin Psychopharmacol (1993)13:145-149.
50. de Montigny C: Chotecystokinin tetrapeptide induces panic-tike attacks in healthy volunteers. Arch Gen Psychiatry(1989) 46:511-517.
51. van Megen HJ, Westenberg HG, Den Boer JA, Kahn RS: The panicinducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder. Eur Neuropsychopharmacol (1996) 6:187-94.
52. Bradwejn J, Koszycki D: Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am J Psychiatry (1994) 151:261-263.
53. van Megen HJGM, Westenberg HGM, Den Boer JA, Slaap B, Scheepmakers A: Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacology (1997)129:357-364.
54. Bradwejn J, Koszycki D, Couetoux du Tertre A, van Megen H, den Boer J, Westenberg H: The panicogenic effects of cholecystokinintetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry (1994) 51:486-93.
55. Lines C, Challenor J, Traub M: Cholecystokinin and anxiety in normal volunteers: An investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365,260. Br J Clin Pharmacol (1995) 39:235-242.
56. Bradwejn J, Koszycki D, Paradis M, Reece P, Hinton J, Sedman A: Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Blot Psychiatry (1995) 38:742-746.
57. Trivedi BK, Padia JK, Holmes A, Rose S, Wright DS, Knton JP, Pritchard MC, Eden JM, Kneen C, Webdale L, Suman-Chauhan N, Boden P. Singh L, Field MJ, Hill D: Second generation "peptokT CCK-B receptor antagonists: identification and development of N(adamantyloxycarbonyl>a-fnethyl-(R>-tryptophan derivative (CM 015) with an improved pharmacokirtetic profile. JAfedC/7e/n(1998)41:3&45.
58. Semple G, Ryder H, Rooker DP, Batt AR, Kendrick DA, Szelke M, Ohta M, Satoh M, Nishkla A, Akuzawa S, Miyata K: (3R)-M(1-(tertbutylcarbonylmethyl)-2>dihydro-2-oxo-5-(2-pyridyr)-1/f 1,4benzodiazepin-3-yi)-Ar methylamino)phenylXrea (YF476): a potent and oraBy active gastrin/CCK-B antagonist J Med Chem (1997) 40:331341.
59. Horwell D, Pritchard M, Raphy J, Ratcliffe G: 'Targeted' molecular diversity: design and development of non-peptide antagonists for chotecystokinin and tachykinin receptors. Immunopharmaco/ogy (1996)33:68-72.
60. Jackson HC, Nutt DJ: Anxiety and panic disorders. In: Neurotherapeutics: emerging strategies. Basic and clinical perspectives, Pullan L & Patel J (Eds), Humana Press, New Jersey (1995) 85-131.
61. Degonda M, Angst J: The Zurich study. XX. Social phobia and agoraphobia. EurArch Psychiatry Clin Weurosc/(1993) 243:95-102.
62. Davidson JR, Potts N, Richichi E, Krishnan R, Ford SM, Smith R, Wilson WH: Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol (1991 ) 13:423-428.
63. LJebowftz MR, Fyer AJ, German JM, Campeas R, Levin A: Phenelzine in social phobia. J Clin Psychopharmacol (1986) 6:93-98.
64. Versiani M, Mundim FD, Nardi AE, LJebowitz MR: Tranylcypromine in social phobia. J Clin Psychopharmacol (1988) 8:279-283.
65. Wesner RB, Noyes R Jr. Imipramine an effective treatment for illness phobia. J Affect Disord (1991) 22:4348.
66. Simpson HB, Schneier FR, Campeas RB, Marshall RD, Fallen BA, Oavies S, Klein DF, LJebowitz MR: Imipramine in the treatment of social phobia. J Clin Psychopharmacol (1998) 18:132-135.
67. Ameringen MV, Mancini C, Farvolden P, Oakman J: Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI. Exp Opin Invest Drugs (2000) 9:2215-2231. • A recent review on drugs in development for social phobia including current options, such as SSRIs, and new and promising directions such as substance P antagonists, GABA agonists and CRF antagonists.
68. van Vliet IM, den Boer JA, Westenberg HG: Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (1994) 115:128-134.
69. Stein MB, Fyer AJ, Davidson JRT, Pollack MH, Wiita B: Fluvoxamine treatment of social phobia (social anxiety disorder): A doubleblind, placebo-controlled study. Am J Psychiatry (1999) 156:756-760.
70. Stein MB, LJebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I: Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. J Am Med Assoc (1998) 280:708-713.
71. Baldwin D, Bobes J, Stein DJ, Scharwachter I, Faure M: Paroxetine in social phobia/social anxiety disorder. Randomised, double- blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry (1999)175:120-126.
72. Stein MB, Charter MJ, Hazen AL, Kroft CDL, Châle RA, Coté D, Walker JR: Paroxetine in the treatment of generalized social phobia: Openlabel treatment and double-blind placebo-controlled discontinuation. J Clin Psychopharmacol (1996) 16:218-222.
73. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC: Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry (1995) 152:1368-1371.
74. van Ameringen M, Mancini C, Streiner D: Sertraline in social phobia. J Affect D/sord(1994) 31:141-145.
75. Connor KM, Hidalgo RB, Crockett B, Malik M, Katz RJ, Davidson JR: Predictors of treatment response in patients with posttraumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry (2001) 25:337-345.
76. Davidson J: Drug therapy of post-traumatic stress disorder. Br J Psychiatry (1992) 160:309-314.
77. Hidalgo RB, Davidson JR: Selective serotonin reuptake inhibitors in post-traumatic stress disorder. J Psychopharmacol (2000) 14:70-76. • A recent review of SSRIs as first-line therapy, alleviating the core symptoms of PTSD, and being effective for the treatment of comorbid disorders such as depression, panic disorder and social phobia." '
78. van der Kolk BA, Dreyfuss D, Michaels M, Shera D, Berkowitz R, Fisler R, Saxe G: Fluoxetine in post-traumatic stress disorder. J Clin Psychiatry (1994) 55:517-522.
79. Connor KM, Sutherland SM, Tupler LA, Malik ML, Davidson JR: Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study. Br J Psychiatry (1999) 175:17-22.
80. Davidson JR, Malik ML, Sutherland SN: Response characteristics to antidepressants and placebo in post-traumatic stress disorder. In! Clin Psychopharmacol(1997) 12:291-296.
81. Stem L, Zohar J,-Cohen R, Sasson Y: Treatment of severe, drug resistant obsessive compulsive disorder with the 5HT1D agonist sumatriptan. Eur Neuropsychopharmacol (1998) 8:325-328.
82. Pigott TA, Seay S: Pharmacotherapy of obsessive compulsive disorder. Int Rev Psychiatry (1997) 9:133-147.
83. Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC: Efficacy and tolerability of serotonin transport inhibitors in obsessivecompulsive disorder: A meta-analysis. Arch Gen Psychiatry (1995) 52:53-60.
84. Papart P, Ansseau M: Milnacipran et trouble obsessionel-compulsH: Etude d'un cas. Psychiatr Psychobiol (1990) 5:325-327.
85. Zohar J, Insel TR: Drug treatment of obsessive-compulsive disorder. J Affect Disord (1987) 13:193-202.
86. Moret C, Briley M: The possible role of 5-HT, receptors in psychiatric disorders and their potential as a target for therapy. Eur JPharmacol(2000) 404:1-12.
87. Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL: Serotonergic responsivhy in obsessive-compulsive disorder. Comparison of patients and healthy controls. Arch Gen Psychiatry (1987)44:946-951.
88. Zohar J, Insel TR, Zohar-Kadouch RC, Hill JL, Murphy DL: Serotonergic responsivhy in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. Arch Gen Psychiatry (1988)45:167-172.
89. Dolberg OT, lancu I, Sasson Y, Zohar J: The pathogenesis and treatment of obsessive-compulsive disorder. Clin Neuropharmacol (1996)19:129-147.
90. Zohar J: Is 5-HT10 involved in obsessive-compulsive disorder? Am Coll Neuropsychopharmacol (1996) 6:54-55.
91. Dolberg OT, Sasson Y, Cohen R, Zohar J: The relevance of behavioral probes in obsessive-compulsive disorder. Eur J Neuropsychopharmacol (1995) 5:161-162.
92. Stein DJ, Van Heerden B, Wessels CJ, Van Kradenburg J, Warwick J, Wasserman HJ: Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor. Prog Neuropsychopharmacol Biol Psychiatry (1999) 23:1079-1099.
93. Breier A, Paul SM: The GABA-A/benzodiazepine receptor implications for the molecular basis of anxiety. J Psychiatr Res (1990)24:91-104.
94. Griebel G, Sanger DJ, Perrault G: Further evidence for differences between non-selective and BZ-1 (omegal) selective, benzodiazepine receptor ligands in murine models of 'state' and 'trait' anxiety. Neuropharmacology (1996) 35:1081-1091.
95. Sanger DJ, Zivkovic B: Differential development of tolerance to the depressant effects of benzodiazepine and non-benzodiazepine agonists at the omega (BZ) modulatory sites of GABAA receptors. Neuropharmacology (1992) 31:693-700.
96. Pompeiano M, Palacios JM, Mengod G: Distribution of the serotonin 5-HT, receptor family mRNAs: comparison between 5-HTu and 5HT,. receptors. Brain Res Mol Brain Res (1994) 23:163-178.
97. Sharma A, Punhani T, Föne KG: Distribution of the 5hydroxytryptamirte receptor protein in adult rat brain and spinal cord determined using a receptor-directed antibody: Effect of 5,7dihydroxytryptamine. Synapse (1997) 27:45-56.
98. Martin JR, Bös M, Jenck F, Moreau J, Mutel V, Sleight AJ, Wichmann J, Andrews JS, Berendsen HH, Broekkamp CL, Ruigt GS, Kohler C, Delft AM: 5-HT receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp T/?er(1998) 286:913-924.
99. Jenck F, Moreau J-L, Wichmann J, Stadier H, Martin JR, Bös M: Brain 5-HT,. receptors: potential role in anxiety disorders. In: Anxiolytics, Briley M & Nutt D (Eds), Birkhäuser Verlag, Basel (2000) 119-137. • A state of the art review showing that selective 5-HT2 receptor ligands generate interest by their innovation and therapeutic opportunities.
100. Jenck F, Bös M, Wichmann J, Stadier H, Martin JR, Moreau J-L: The rote of 5-HTjç receptors in affective disorders. Exp Opln Invest Drugs (1998)7:1587-1599.
101. Bös M, Jenck F, Martin JR, Moreau Jl_ Sleight AJ, Wichmann J, Widmer U: Novel agonists of 5HTK receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yI)-1methytethylamines and 2-(indeno[1,2-b]pyrrol-1-yl}-1methylethylamines. Improved therapeutics for obsessive compulsive disorder. J Med Çhem (1997) 40:2762-2769.
102. Bös M, Jenck F, Martin JR, Moreau J-L, Mutel V, Sleight A, Widmer U: Synthesis, pharmacology and therapeutic potential of 10methoxypyrazino[1,2-a]indotes, partial agonists at the 5-HTK receptor. EurJMedChem (1997) 32:253-261.
103. Bromidge SM, Dabbs S, Davies DT, Davies S, Duckworth DM, Forbes IT, Gaster LM, Ham P, Jones GE, King FD, Mulholland KR, Saunders DV, Wyman PA, Blaney FE, Clarke SE, Blackburn TP, Holland V, Kennett GA, üghtowler S. Middlemiss DN, Trail B, Riley GJ, Wood MD: Biarylcarbamoylindolines are novel and selective 5-HTK receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3pyridyl)oxy]-5-pyridyi]carbamoyl}-£- trifluorometnylindoline (SB243213) as a potential antidepressant/anxiolytic agent. J Med Chem (2000)43:1123-1134.
104. Pàlvimaki EP, Majasuo H, Kuoppamaki M, Mannisto PT, Syvalahti E, HietaJa J: Deramciclane, a putative anxiolytic drug, is a serotonin 5HTK receptor inverse agonist but fails to induce 5-HTK receptor down-regulation. Psychopharmacology (1998) 136:99-104.
105. Briley M, Chopin P, Moret C: The rote of serotonin in anxiety: behavioural approaches. In: New Concepts in Anxiety, Briley M & Rie SE (Eds), Macmillan Press, London (1991) 56-73.
106. Broekkamp CL, Berendsen HH, Jenck F, Van Delft AM: Animal models for anxiety and response to serotonergic drugs. Psychopatho/ogy (1989)22(SuppM):2-12.
107. Briley M, Chopin P, Marien M, Moret C: Functional neuropharmacology of compounds acting at 5-HT1MJ receptors. In: Serotoninergic neurons and 5-HT receptors in the CNS, Baumgarten HG & Göthert M (Eds), Springer-Verlag, Berlin (1997) 269-291.
108. Benjamin D, La! H, Meyerson LR: The effects of 5-HT,. characterizing agents in the mouse elevated plus-maze. Life Sc/(1990) 47:195-203.
109. Rodgers RJ, Cole JC, Cobain MR, Daly P, Doran PJ, Eells JR, Wallis P: Anxiogenic-like effects of fluprazine and eltoprazine in the mouse elevated plus-maze: profile comparisons with 8-OH-DPAT, CGS 12066B,TFMPPand mCPP. Behav Pharmacol (1992) 3:621-634.
110. Olivier B, Molewijk HE, van der Heyden JA, van Oorschot R, Ronken E, Mos J, Miczek KA: Ultrasonic vocalizations in rat pups: effects of serotonergic ligands. Neurosci Biobehav Rev (1QS8) 23:215-227.
111. Fish EW, Sekinda M, Ferrari PF, Dirks A, Miczek KA: Distress vocalizations in maternally separated mouse pups: modulation via 5-HT1A, 5-HT, and GABAA receptors. Psychopharmacology (2000) 149:277-285.
112. Chopin P, Colpaert FC, Moret C, Marien M: Interactions between 5HT,B and benzodiazepine receptor ligands in the light/dark box anxiety model in mice. Sec Neurosci Abs (1998) 24:601.
113. Rex A, Marsden CA, Fink H: Effect of diazepam on cortical 5-HT release and behaviour in the guinea-pig on exposure to the elevated plus maze. Psychopharmacology (1993) 110:490-496.
114. Feuerstein TJ, Huring H, van Vefthoven V, Lucking CH, Landwehrmeyer GB: 5-HT,D-like receptors inhibit the release of endogenously formed ['H]GABA in human, but not in rabbit, neocortex. Neurosci Lett (1996) 209:210-214.
115. Clément Y, Kia KH, Daval G, Vergé D: An autoradiographic study of serotonergic receptors in a murine genetic model of anxietyrelated behaviors. Brain Res (1996) 709:229-242.
116. Castanon N, Ramboz S, Saudou F, Hen R: Behavioral consequences of 5-HT, receptor gene deletion. In: Serotoninergic neurons and 5-HT receptors in the CNS, Baumgarten HG & Göthert M (Eds), Springer-Verlag, Berlin (1997) 351-365.
117. Stark KL, Hen R: Knockout corner. Int J Neuropsychopharmacol (1999)2:145-150.
118. Ramboz S, Saudou F, Amara DA, Beizung C, Segu L, Misslin R, Buhot MC, Hen R: 5-HT,. receptor knock out-behavioral consequences. Behav Brain Res (1996) 73:305-312.
119. Zhuang X, Gross C, Santarelli L, Compan V. Trillat AC, Hen R: Altered emotional States in knockout mice lacking 5-HTu or 5-HT receptors. Neuropsychopharmacology(1999) 21:52S-60S.
120. Brunner D, Buhot MC, Hen R, Hofer M: Anxiety, motor activation and maternal-infant interactions in 5-HT, knockout mice. Behav Neurosci (1999) 113:587-601.
121. Sarhan H, Pillion G: The therapeutic potential of 5-HT, autoreceptors and heteroreceptors and 5-HT moduline in CNS disorders. CNS Spectrums (1998) 3:50-58. • A useful summary of the potential of 5-HT moduline, an endogenous modulator of serotonin activity. Its biochemical and pharmacological properties are described and its potential role in psychiatric pathophysiologyparticularly anxiety-and its therapeutic implications are presented.
122. Segiin L, Seznec JC, Fiffion G: The endogenous cerebral tetrapeptide 5HT-moduKne reduces in vivo the functional activity of central 5-HT, receptors in the rat Neurosci Res (1997) 27:277-280.
123. Crawley JN: Comparative distribution of cholecystokinin and other neuropeptides. Ann WYMcadSc/(1985) 448:1-8.
124. Griebe! G: Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol Ther(1999) 82:1-61.
125. de Montigny C: Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings. Arch Gen Psychiatry (1989) 46:511-517.
126. De Souza EB: Corticotropin-releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. Psychoneuroendocrinology (1995) 20:789-819.
127. Argyropoulos S, Nutt DJ: Peptide receptors as targets for anxiolytic drugs. In: Anxiolytics, Briley M & Nutt D (Eds) Birkhäuser Verlag, Basel (2000) 151-175.
128. Blomqvist AG, Herzog H: Y-receptor subtypes-how many more? Trends Neurosci (1997) 20:294-298.
129. Wahlestedt C, Pich EM, Koob GF, Yee F, Heilig M: Modulation of anxiety and neuropeptide ' Y-Y, receptors by antisense oligodeoxynucleotides. Science (1993) 259:528-531.
130. Grundemar L, Hâkanson R: Neuropeptide Y effector systems: Perspectives for drug development Trends Pharmacol Sd(1994) 15:153159.
131. Ehlers CL, Somes C, Lopez A, Kirby D, Rivier JE: Electrophysiological actions of neuropeptide Y and its analogs: new measures for anxiolytic therapy? Neuropsychopharmacology (1997) 17:34-43.
132. Widerlov E, Lindstrom LH, Wahlestedt C, Ekman R: Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia. J Psychiatry Res (1988) 22:69-79.
133. Penney JB: Neurochemical neuroanatomy. In: Neuropsychiatry, Fogel BS, Schiffer RB, Rao SM (Eds), Williams and Wilkins, Baltimore (1996) 145-171.
134. Wahlestedt C: Reward for persistence in substance P research. Science (1998) 281:1624-1625.
135. Stout SC, Owens MJ, Nemeroff CB: Neurokinin, receptor antagonists as potential antidepressants. Annu Rev Pharmacol Toxicol (2001) 41:877-906.
136. Altemus M, Pigott T, L'Heureux F, Davis CL, Rubinow DR, Murphy DL, Gold PW: CSF somatostatin in obsessive-compulsive disorder. Am J Psychiatry (1993) 150:460-164.
137. Watanabe M, Inoue Y, Sakimura K, Mishina M: Distinct spatiotemporal distributions of the NMDA receptor channel subunH mRNAs in the brain. Ann NYAcadSci (1993) 707:463-466.
138. Monyer H, Bumashev N, Laune DJ, Sakmann B, Seeburg PH: Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron (1994) 12:529-540.
139. Boyer PA, Skolnick P, Fossom LH: Chronic administration of imipramine and chalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain - A quantitative in situ hybridization study. J Mol Neurosci (1998) 10:219-233.
140. Meguro H, Mon H, Araki K, Kushiya E, Kutsuwada T, Yamazaki M, Kumanishi T, Arakawa M, Sakimura K, Mishina M: Functional characterization of a heteromeric NMDA receptor channel expressed from cloned cDNAs. Nature (1992) 357:70-74.
141. Williams K, Zappia AM, Pritchett DB, Shen YM, Molinoff PB: Sensitivity of the N-methyl-D-aspartate receptor to poryamines is controlled by NR2 subunits. Mo!Pharmacol (1994) 45:803-809.
142. Skolnick P: Glutamate receptor ligands. In: Anxiolytics, Briley M & Nutt D (Eds), Birkhäuser Vertag, Basel (2000) 139-150. • A review of the subject which presents NMDA receptor biology and, with preclinical studies, the anxiogenic activation of NMDA receptors and the potential anxiolytic actions of NMDA receptor antagonists or Group II metabotropic glutamate receptor agonists.
143. LJebman JM, Bennett DA: Anxiolytic actions of competitive Nmethyl-D-aspartate receptor antagonist: A comparison with benzodiazepine modulators and dissociate anesthetics. In: Frontiers in excitatory ammo acid research, Cavalheiro E, Lehmann J, Turski L (Eds), Alan LJss, New York (1988) 301-308.
144. Bennett DA, Amrick CL 2-Amino-7-phosphonoheptanoic acid (AP7) produces discriminative stimuli and anticonflict effects similar to diazepam. Life Sc/(1986) 39:2455-2461.
145. Trullas R, Jackson B, Skolnick P: Anxiolytic properties of 1aminocyclopropanecarboxylic acid, a ligand at strychnineinsensitive glycine receptors. Pharmacol Biochem Behav (1989) 34:313-316.
146. Corbett R, Dunn R: Effects of HA-966 on conflict, social interaction, and plus maze behaviors. Drug DevRes (1991) 24:201-205.
147. Kotflinska J, Uljequist S: A characterization of the anxiolytic-like actions induced by the novel NMDA/glycine site antagonist, L701,324. Psychopharmacology(1998) 135:175-181.
148. Guimaraes FS, Carobrez AP, Deaguiar JC, Graeff FG: Anxiolytic effect in the elevated plus-maze of the NMDA receptor antagonistAP7 microinjected into the dorsal periaqueductal grey. Psychopharmacology(199ty 103:91-94.
149. Teixeira KV, Carobrez AP: Effects of glycine or (±)-3-amino-1hydroxy-2-pyrrolidone microinjections along the rostrocaudal axis of the dorsal periaqueductal gray matter on rats' performance In the elevated plus-maze task. Behav Neurosci (1399) 113:196-203.
150. Schoepp DO, Jane DE, Monn JA: Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology (1999)38:1431-1476.
151. Monn JA, Valu MJ. Massey SM, Wright RA, Salhoff CR, Johnson BG, Howe T, Alt CA, Rhodes GA, Robey RL, Griffey KR, Tizzano JP, Kallman MJ, Helton DR, Schoepp DD: Design, synthesis, and pharmacological characterization of (+}-2aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem (1997) 40:528-537.
152. Heiton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ: Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp 7her(1998) 284:651-660.
153. Klodzinska A, Chojnacka-Wojcik E, Palucha A, Branski P, Popik P, Pile A: Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology (1999) 38:1831 -1839.
154. Klodzinska A, Chojnacka-Wojcik E, Pile A: Selective group II glutamate metabotropic receptor agonist LY354740 attenuates pentetrazole- and picrotoxin-induced seizures. Pol J Pharmacol (1999)51:543-545.